Literature DB >> 9067496

Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance.

M A Haidar1, H El-Hajj, C E Bueso-Ramos, T Manshouri, A Glassman, M J Keating, A Maher.   

Abstract

The MDM-2 oncoprotein exists in an autoregulatory feedback loop with the tumor suppressor protein p53. Therefore, intracellular levels of these two proteins may play important roles in cell proliferation and tumorigenesis. Several MDM-2 proteins (Mr 35-100 Kd) have been demonstrated in human cell lines. We report here the expression profile of MDM-2 and p53 proteins in 87 cases of chronic lymphocytic leukemia (CLL) as detected by immunoblot analysis. The MDM-2 proteins (p57, p59, p67, and p90) were found to be overexpressed in different combinations in 56/87 (64%) of cases of CLL when compared with normal volunteers. The MDM-2 protein p57 was predominantly overexpressed 46/87 (53%) in CLL. In 22/87 (25%) cases of CLL p57 was overexpressed alone, and in 24/87 (28%) cases it was co-overexpressed with other MDM-2 proteins p59/p67/p90. Six of the 87 cases of CLL showed overexpression of the tumor suppressor protein p53 by immunoblot analysis, and five of those cases also co-overexpress MDM-2 protein p57. No statistically significant correlation of MDM-2 protein overexpression to clinical disease stage and history of previous chemotherapy of CLL patients has been found. However, considering the oncogenic potential of overexpressed MDM-2 proteins, a possible role of MDM-2 proteins in the promotion of CLL disease remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067496     DOI: 10.1002/(sici)1096-8652(199703)54:3<189::aid-ajh3>3.0.co;2-s

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

Review 1.  The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Cheng Wang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

2.  Verification of gene expression profiles for colorectal cancer using 12 internet public microarray datasets.

Authors:  Yu-Tien Chang; Chung-Tay Yao; Sui-Lung Su; Yu-Ching Chou; Chi-Ming Chu; Chi-Shuan Huang; Harn-Jing Terng; Hsiu-Ling Chou; Thomas Wetter; Kang-Hua Chen; Chi-Wen Chang; Yun-Wen Shih; Ching-Huang Lai
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 3.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

4.  Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels.

Authors:  Moussa Alkhalaf; Abdalla M El-Mowafy; Laila A Abou-Zeid
Journal:  J Mol Genet Med       Date:  2005-08-19

5.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Teresa McQueen; Susan O'Brien; William Plunkett; Michael Andreeff
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

Review 6.  P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Authors:  Stefania Trino; Luciana De Luca; Ilaria Laurenzana; Antonella Caivano; Luigi Del Vecchio; Giovanni Martinelli; Pellegrino Musto
Journal:  Front Pharmacol       Date:  2016-12-16       Impact factor: 5.810

7.  Investigation of MDM2 Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia

Authors:  Şule Darbaş; Çiğdem Aydın; Ozan Salim; Sibel Berker Karaüzüm
Journal:  Turk J Haematol       Date:  2018-10-16       Impact factor: 1.831

8.  Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.

Authors:  Carmela Ciardullo; Erhan Aptullahoglu; Laura Woodhouse; Wei-Yu Lin; Jonathan P Wallis; Helen Marr; Scott Marshall; Nick Bown; Elaine Willmore; John Lunec
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

9.  Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study.

Authors:  Michael J Groves; Stephanie F Maccallum; Michael T Boylan; Sally Haydock; Joan Cunningham; Keith Gelly; Duncan Gowans; Ron Kerr; Philip J Coates; Sudhir Tauro
Journal:  J Cancer       Date:  2012-08-24       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.